AMONDYS 45 uses Sareptas proprietary phosphorodiamidate morpholino oligomer PMO chemistry and exonskipping technology to bind to exon 45 of dystrophin premRNA resulting in exclusion or skipping of this exon during mRNA processing in patients with genetic mutations that are amenable to exon 45 skipping